SecBot SecBot

PHVS

Pharvaris N.V.
Nasdaq· Pharmaceutical Preparations· Inc. P7· CIK 0001830487 Biotech & Drug Discovery
$32.44 −0.92 (−2.76%)
Nov 16 4:00 PM ET · prev $33.36
Market cap
$2.4B
Mid cap
Consensus
Buy
95% Buy or better · 21 analysts
Median target
🔒 Subscribers only
1 year
+30.2%
from $24.92 · Nov 17
30 days
+9.0%
from $29.77
52-week range
$23.68–38.86
−17% from high · low Dec 10
Avg volume 20D
561.9K
Oct 30 spike 1.48M
Short interest
2.54M
≈3.6% of shares · +3.0%
Days to cover
3.6
at average volume
Insider net
−$20.5M
0 buyers · 10 sellers · since Jun 30
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
41
analyzed by SecBot
SecBot read BEARISH 19 reports · 90 days
Balance 11 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 10/19

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    10 insiders sold $20.5M.

  • InstitutionsBULLISH

    Q3 2026: 27 added (1 new), 4 trimmed or exited.

  • AnalystsBULLISH

    20 of 21 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.773 → −$0.703 over 90 days. 3 up, 8 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.0% to 2.54M shares. 3.6 days to cover, ≈3.6% of shares.

  • TrendRANGE

    2% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD966,721$30.7M
MORGAN STANLEYDOUBLED412,829$13.1M
BNP Paribas Asset Management Holding S.A.DOUBLED409,516$13.0M
JANE STREET GROUP, LLCDOUBLED377,093$12.0M
UBS Group AGADD349,068$11.1M
Qube Research & Technologies LtdDOUBLED282,873$9.0M
TD ASSET MANAGEMENT INCADD71,226$2.3M
Swiss National BankADD49,457$1.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 95% rate it Buy or better
Strong Buy10Buy10Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 23, 2026B of A Securities
UPGRADE
UPGRADEBuy
Sep 10, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 9, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Sep 9, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Sep 9, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Sep 9, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$20.5M
sold · 10 insiders
DateInsiderTypeValue
Nov 12, 2026
Lu Peng
President
Nov 12, 2026
TAX W/H$4.0K
Nov 11, 2026
Lu Peng
President
Nov 11, 2026
TAX W/H$3.7K
Oct 12, 2026
Lu Peng
President
Oct 12, 2026
TAX W/H$3.6K
Oct 11, 2026
Lu Peng
President
Oct 11, 2026
TAX W/H$3.4K
Sep 23, 2026
Monges Viviane
Director
Sep 23, 2026
EXERCISE$96.4K
Sep 23, 2026
Monges Viviane
Director
Sep 23, 2026
SELL$395.5K
Sep 22, 2026
Lu Peng
President
Sep 22, 2026
EXERCISE$117.3K
Sep 22, 2026
Schikan Johannes Gerardus Christiaan Petrus
Director
Sep 22, 2026
EXERCISE$16.0K

Earnings setup

Estimates
−$0.70
EPS estimate, this quarter
+9%
estimate change, 90 days
3↑ 8↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.70-$0.76–-$0.65+8.8%$0.00
Next Q-$0.79-$0.96–-$0.66+1.2%$0.00
Current FY-$2.64-$2.79–-$2.46+4.7%$0.00
Next FY-$2.69-$3.45–-$2.19+1.1%$33.2M

Short side

FINRA· Oct 30, 2026
2,539,475
shares short
+3.0%
vs prior settlement
3.6
days to cover
≈3.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
General Atlantic filed Amendment No. 4 to its Schedule 13G for Pharvaris N.V., reporting a 0.6% stake (437,458…
SC 13G/A · Impact 5/10
Nov 12, 2026 Press
Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rate by…
Impact 7/10
Nov 12, 2026 M&A
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma
Nov 12, 2026 SEC
Pharvaris reported Q3 2026 results showing a net loss of EUR 47.4M ($0.67 per share), wider than the EUR 37.1M loss in…
6-K · Impact 4/10
Nov 12, 2026 Insider
Lu Peng surrendered for taxes 117 shares
President @ $34.18 ($4.0K)
Nov 11, 2026 Insider
Lu Peng surrendered for taxes 109 shares
President @ $33.99 ($3.7K)
Oct 12, 2026 Insider
Lu Peng surrendered for taxes 117 shares
President @ $31.10 ($3.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

41 filings · 10 press releases · 1 bullish · 13 bearish · 1 mixed · 26 neutral
All PHVS filing & press-release reports (51)